linkedin

Resource Library

Whitepapers

Fundamental Considerations for Bispecific Antibody-based Cell Line Development

WHITE PAPER Fundamental Considerations for Bispecific Antibody-based Cell Line Development, Seahee Kim, Head of Cell Line Development 

WHITE PAPER

Fundamental Considerations for Bispecific Antibody-based Cell Line Development
Seahee Kim
Head of Cell Line Development

 

The innovative dual specificity of bispecific antibodies opens a range of applications to serve the currently unmet needs of patients. However, due to the complexity of controlling advanced biotherapeutics, the industry still faces several challenges, including difficulty in maintaining the affinity of parental mAbs and mispairing. In this whitepaper, Seahee Kim, our principal scientist in cell line development, delves into the key considerations for upholding excellence in the quality of bispecific antibody-based cell line development.  

 

 

WHITRPAPER 

WHITRPAPER

Fundamental Considerations for Bispecific Antibody-based Cell Line Development
Seahee Kim
Head of Cell Line Development

 

The innovative dual specificity of bispecific antibodies opens a range of applications to serve the currently unmet needs of patients. However, due to the complexity of controlling advanced biotherapeutics, the industry still faces several challenges, including difficulty in maintaining the affinity of parental mAbs and mispairing. In this whitepaper, Seahee Kim, our principal scientist in cell line development, delves into the key considerations for upholding excellence in the quality of bispecific antibody-based cell line development.  

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved